General Hospital Of Patras Agios Andreas
- Address
- Kalavriton 37, 265 00 Pátrai, Greece
General Hospital Of Patras Agios Andreas - Oncology Research Center
The General Hospital Of Patras Agios Andreas operates as a comprehensive oncology research center with extensive expertise in advanced cancer therapeutics and innovative treatment strategies. The center specializes in conducting pivotal phase 2 and phase 3 clinical trials across multiple tumor types, with particular emphasis on precision medicine approaches and targeted therapies. Their research portfolio demonstrates a strong commitment to addressing complex malignancies through cutting-edge immunotherapy, antibody-drug conjugates, and combination treatment protocols.
- Breast Cancer: Advanced trials in ER-positive/HER2-negative breast cancer with ESR1 mutations, HER2-positive breast cancer with residual disease, and novel antibody-drug conjugate therapies
- Lung Cancer: KRAS G12C-mutant non-small cell lung cancer (NSCLC) and squamous NSCLC with immunotherapy combinations
- Genitourinary and Gynecologic Oncology: Advanced urothelial cancer, high-risk locally advanced cervical cancer with chemoradiotherapy, and post-immunotherapy endometrial cancer
- Hematologic Malignancies: Relapsed/refractory multiple myeloma with bispecific antibody therapy
The center demonstrates proficiency in evaluating immunotherapy combinations, targeted molecular therapies, and CDK4/6 inhibitor resistance mechanisms. Their clinical trial portfolio includes studies examining progression-free survival, overall survival, and objective response rates using advanced methodologies such as blinded independent central review. Beyond oncology, the institution also contributes to ophthalmology research, including trials for open angle glaucoma and ocular hypertension, showcasing their multidisciplinary clinical research capabilities.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 43 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 43 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1AstraZeneca AB2active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC3trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in General Hospital Of Patras Agios Andreas
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy | Gilead Sciences Inc. | Phase III | Not Recruiting | Jan 2025 | — |
IMP list
lock Showing 1 of 43 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 4 | Unknown | 2019-05-07 | 2025-12-15 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.